Kedalion Therapeutics is a clinical-stage, venture-funded ophthalmic drug company based in Menlo Park, CA. Kedalion's AcuStream technology delivers topical drugs to the eye in a precise and accurate manner that enables comparable efficacy with an 80% reduction in dose compared to standard drops, and a significantly improved side effect profile along with patient comfort and convenience following self-administration.

Biotechnology

Kedalion Therapeutics

Mark Blumenkranz

Mark Murray

Ehud Ivri

Casey Dougan

Joseph Gilbert

Reynaldo Quintana

Scientific Team

Leadership Team

Strategic Advisory Team

Teams at Kedalion Therapeutics

Scientific Team

Leadership Team

Strategic Advisory Team